Compare PDS & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDS | GLUE |
|---|---|---|
| Founded | 1951 | 2019 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 918.1M | 1.1B |
| IPO Year | N/A | 2021 |
| Metric | PDS | GLUE |
|---|---|---|
| Price | $68.38 | $16.40 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $98.00 | $15.00 |
| AVG Volume (30 Days) | 76.5K | ★ 812.4K |
| Earning Date | 10-22-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.98 | 0.25 |
| Revenue | ★ $1,316,232,437.00 | $181,538,000.00 |
| Revenue This Year | N/A | $81.52 |
| Revenue Next Year | $2.89 | N/A |
| P/E Ratio | ★ $23.04 | $64.61 |
| Revenue Growth | N/A | ★ 1112.27 |
| 52 Week Low | $36.20 | $3.50 |
| 52 Week High | $71.77 | $18.15 |
| Indicator | PDS | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 58.98 |
| Support Level | $56.10 | $15.21 |
| Resistance Level | $71.77 | $17.75 |
| Average True Range (ATR) | 2.29 | 0.88 |
| MACD | 0.49 | -0.17 |
| Stochastic Oscillator | 77.87 | 42.86 |
Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.